FY2025 · ended Dec 31, 2025 · Revenue $13.86M, -14.2% YoY · Filed Mar 23, 2026
Pyxis Oncology, Inc. (PYXS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $13.9 million and a net loss of $79.6 million. Free cash flow was -$63.5 million. As of Sep 30, 2026 it held $55.6 million in cash and investments and $17.4 million in total debt.
Revenue
$13.86M
-14.2% vs prior year
Net income
$-79.62M
-3.0% vs prior year
Operating cash flow (TTM)
$-70.93M
+2.0% vs year-ago TTM
Free cash flow (TTM)
$-70.93M
+2.0% vs year-ago TTM
EPS
$-1.28
+3.0% vs prior year
Dividend per share
None
Shares outstanding
62.83M
+2.0% vs prior year
Net cash
$38.17M
as of Sep 30, 2026
Operating margin
-609.2%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PYXS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782223
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | -$76.0M |
| Diluted EPS | -$1.28 | -$1.32 | -$1.85 | -$3.65 | — |
| Operating cash flow | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
| Stockholders' equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M |
| Cash and investments | $66.9M | $126.9M | $119.3M | $179.3M | $274.7M |
| Total debt | $18.7M | $20.2M | $21.3M | $18.9M | $165,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 2, 2026 | Jun 30, 2026 |
All 354 Pyxis Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.